Abbisko Cayman Limited (2256.HK)
HKD 4.46
(-3.67%)
HKD 4.46
(-3.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -431.58 Million CNY | 13.39% |
| 2022 | -498.29 Million CNY | 72.39% |
| 2021 | -1.8 Billion CNY | -155.38% |
| 2020 | -706.81 Million CNY | -428.69% |
| 2019 | -133.69 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 103.39 Million CNY | 0.0% |
| 2024 Q1 | 103.39 Million CNY | 192.74% |
| 2023 Q4 | -111.49 Million CNY | 0.0% |
| 2023 FY | -431.58 Million CNY | 13.39% |
| 2023 Q3 | -111.49 Million HKD | -6.9% |
| 2023 Q2 | -104.29 Million CNY | 0.0% |
| 2023 Q1 | -104.29 Million CNY | 23.87% |
| 2022 Q3 | -137 Million CNY | -23.64% |
| 2022 Q2 | -110.8 Million CNY | 0.0% |
| 2022 FY | -498.29 Million CNY | 72.39% |
| 2022 Q4 | -137 Million CNY | 0.0% |
| 2022 Q1 | -110.8 Million CNY | 84.53% |
| 2021 Q1 | -123.56 Million CNY | 0.0% |
| 2021 Q3 | -716.38 Million CNY | -189.08% |
| 2021 FY | -1.8 Billion CNY | -155.38% |
| 2021 Q4 | -716.38 Million CNY | 0.0% |
| 2021 Q2 | -247.81 Million CNY | -100.56% |
| 2020 Q1 | -56.6 Million CNY | 0.0% |
| 2020 FY | -706.81 Million CNY | -428.69% |
| 2019 FY | -133.69 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 708.927% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 2601.93% |